Why We Invested In Totient aka How AI Can Help Us Produce Drugs Against Cancer And Covid

2 min read

On Sep 10, Totient, an AI-driven drug discovery company, emerged from stealth with the announcement of a key partnership with Ginkgo Bioworks to rapidly identify neutralizing antibodies against COVID-19. Totient has raised more than $10M in seed capital from Tau Ventures and an exceptional mix of other tech and life science investors. Our conviction in Totient is rooted in (1) the ambitious vision, shared by (2) a team which is both scientifically and commercially experienced, (3) and early platform validation. This post is focused specifically on Totient but reflects how we at Tau think about seed-stage investments broadly. 1) Vision…...

This article is free to read

Login to read the full article


By subscribing to our main site, you will also be subscribed to DDIntel - our regular letter showcasing our featured articles and applications.

Amit Garg I have been in Silicon Valley for 20 years -- at Samsung NEXT Ventures, running my own startup (as of May 2019 a series D that has raised $120M and valued at $450M), at Norwest Ventures, and doing product and analytics at Google. My academic training is BS in computer science and MS in biomedical informatics, both from Stanford, and MBA from Harvard. I speak natively 3 languages, live carbon-neutral, am a 70.3 Ironman finisher, and have built a hospital in rural India serving 100,000 people.